CCL2 ELISA Kit

Produktnummer ABIN577069

Human CCL2 ELISA-Kit Colorimetric-Assay zur Quantifizierung von Human CCL2.

Kurzübersicht für CCL2 ELISA Kit (ABIN577069)

Target: CCL2 (Chemokine (C-C Motif) Ligand 2 (CCL2))

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 4-1600 pg/mL

Applikation: ELISA

Produktdetails CCL2 ELISA Kit

Untere Nachweisgrenze: 4 pg/mL

Verwendungszweck: This MCAF enzyme-linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific for MCAF. Standards or samples are then added - the appropriate microtiter plate wells and incubated. MCAF if present, will bind and become immobilized by the antibody pre-coated on the wells. The microtiter plate wells are thoroughly washed - remove unbound MCAF and other components of the sample. In order - quantify the amount of MCAF present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody specific for MCAF is added - each well to

Analytische Methode: Quantitative

Sensitivität: < 4 pg/mL

Bestandteile: Standards: 1 set/2 vials

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konservierungsmittel: Without preservative

Details zu CCL2

Target: CCL2 (Chemokine (C-C Motif) Ligand 2 (CCL2))

Andere Bezeichnung: Monocyte Chemotactic Activating Factor (MCP-1/MCAF)

Hintergrund: Hepatitis resulting from infection with viruses other than Hepatitis A Virus (HAV) and Hepatitis B (HBV) virus was previously referred to as non-A, non-B hepatitis. The first characterised non-A, non-B hepatitis agent was that responsible for parentally transmitted non-A, non-B hepatitis, or what is now called Hepatitis C Virus. This was followed by the cloning of a portion of the fecal-orally-transmitted agent, the Hepatitis E Virus (HEV). Hepatitis E Virus has been referred to as enterically transmitted non-A, non-B hepatitis. Epidemics of enterically transmitted Hepatitis E Virus have been recognised worldwide but occur principally in developing countries. They have been reported in Southeast Asia, central Asia, Africa, Mexico, and Central America. In these areas, contaminated water has been implicated as the principal vehicle of virus transmission. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 1-fold greater than that seen for HAV. Infection with HEV is particularly fatal for pregnant women, for whom the mortality rate can be as high as 1 to 2%

Pathways: Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Immune Effector Process, ER-Nucleus Signaling, Unfolded Protein Response, Phosphorylierungen bei SARS-CoV-2 Infektion